Bio‑Rad (BIO) EVP Evran Sedat Receives RSUs; 606 Shares Withheld

What Happened
Evran Sedat, EVP, Global Supply Chain at Bio‑Rad Laboratories (BIO), received a grant of 4,026 restricted stock units (RSUs) that vested (reported 2026-09-04). Sedat had 1,027 RSUs convert/settle into shares on 2026-09-05 and 864 RSUs convert/settle on 2026-09-06 (total 1,891 shares converted). To cover tax withholding, 329 shares were surrendered on 2026-09-05 ($127,030) and 277 shares on 2026-09-06 ($106,952), for a combined withholding of 606 shares valued at about $233,982 (~$234K). The RSUs carry no exercise price (reported $0.00).

Key Details

• Transaction types: A = Award/Grant (4,026 RSUs reported 2026-09-04); M = derivative conversion/settlement of RSUs (1,027 on 9/5; 864 on 9/6); F = shares withheld/surrendered for tax liability (329 on 9/5 = $127,030; 277 on 9/6 = $106,952).
• Withholding price used: $386.11 per share. Total value withheld ≈ $233,982.
• Shares converted to stock (net of withholding): 1,891 converted minus 606 withheld = 1,285 net shares delivered to the insider.
• Shares owned after transaction: Not stated here — see the official Form 4 for total post-transaction holdings.
• Footnotes: F1–F5 clarify these were RSUs (one RSU = one share), vesting schedule is over four years (25% first anniversary then quarterly/equal installments), and small ESPP purchases (51.2870 and 33.9860 shares) are included in the reported totals.
• Filing: Form filed 2026-09-09 reporting transactions between 2026-09-04 and 2026-09-06 (see official filing for timeliness details).

Context
This was primarily a compensation event (RSU vesting and settlement), not an open-market buy or directional sale. The surrender of shares was for tax withholding — a routine administrative disposition and not necessarily an indication of insider sentiment. The transactions are reported as derivative conversions/settlements (code M) with withholding (code F).